Atezolizumab (Tecentriq)
Each vial contains Atezolizumab 1200 mg
Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with advanced urothelial carcinoma and patients with metastatic non-small cell lung cancer (NSCLC).
- Presentation: Injection
- Strength: 1200 mg/ 20 ml
- Pack Size: 1 vial of 20ml
- Pack Insert: Yes
- Manufacturing License: 1048
View this product at gnhindia.com